Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00463606 · ClinicalTrials.gov registry record · Phase 3
A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 760
- Enrollment target
NCT00463606: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00463606 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 760 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00463606, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 760 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of ABT-335 and rosuvastatin calcium combination therapy to monotherapy in subjects with dyslipidemia.
Primary Outcome
The mean percent change from baseline to the final visit in High-density lipoprotein cholesterol (HDL-C), with ABT-335 135 mg in combination with rosuvastatin 5 mg versus rosuvastatin 5 mg monotherapy.
Interventions
- DRUG ABT-335
- DRUG rosuvastatin calcium
- DRUG ABT-335 and rosuvastatin calcium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 760 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
What the finished NCT00463606 record still lists
NCT00463606 is an interventional study that assigns participants to a tested intervention. The registered 760 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which ABT-335 is the first listed.
NCT00463606 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00463606 about?
NCT00463606 is a clinical study titled "A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia". The purpose of this study is to evaluate the safety and efficacy of ABT-335 and rosuvastatin calcium combination therapy to monotherapy in subjects with dyslipidemia.
What is the current status of trial NCT00463606?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 760 participants. The study started on 2007-04. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00463606?
The interventions under investigation include: ABT-335 (DRUG), rosuvastatin calcium (DRUG), ABT-335 and rosuvastatin calcium (DRUG).
Who is sponsoring clinical trial NCT00463606?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00463606's enrollment target sits among peer trials
760 450th of 2000 higher than 1,546 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02089607 · 760 participants · NA
CAAAs, TAAAs, Aortic Arch Aneurysms or Dissections With Fenestrated/Branched Stent Graft
- NCT04073706 · 760 participants · Phase 3
Sentinel Node Biopsy in Endometrial Cancer
- NCT05129228 · 760 participants · NA
Optical Coherence Tomography of the Saphenous Vein Graft
- NCT05787821 · 760 participants
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia